CIENCIASMEDICASNEWS: FDA DMF Filed CD19 and BCMA Proteins for CAR-T Clinical Trials

jueves, 20 de agosto de 2020

FDA DMF Filed CD19 and BCMA Proteins for CAR-T Clinical Trials

	Antibodies
	The latest antibodies news from News Medical

VHH Antibodies (Nanobodies) Advantages and Limitations

FDA DMF Filed CD19 and BCMA Proteins for CAR-T Clinical Trials

40+ target proteins including CD19, BCMA, MSLN, and EGFR are available at ACROBiosystems for detecting CAR expression and antibody drug screening. High bioactivity verified by FACS, SPR and ELISA with protocol offered for free. ACRO has submitted DMF for its recombinant CD19 and BCMA proteins to FDA, and filed the DMF number as 034936.

Find Out More

Ultra-sensitive neurology assays with Simoa® p-tau181 for improved detection and study of Alzheimer's

Simoa pTau-181 Advantage V2 assay targets the proline rich region of the Tau protein which is highly conserved amongst these isoforms. Tau elevation is observed in the cerebrospinal fluid of patients with neurodegenerative disease and severe head injuries, suggesting its extracellular release during neuronal damage and a role as a biomarker with specificity for brain injury. In Alzheimer’s disease and related neurodegenerative diseases, including chronic traumatic encephalopathy, tau is abnormally phosphorylated and aggregated into bundles of filaments. pTau 181 has been found to be more strongly associated with markers of AD than total tau.

Learn More

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

	Protective anti-prion antibodies found in humans Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies.

	Antibodies from natural controllers appear to play crucial role in eliminating hepatitis B virus Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.

	Scientists describe the mechanism of action of therapeutic antibodies Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

	Beneficial microbes reprogram the B cell repertoire that produce antibodies The mammalian gut is home to trillions of microbes which are essential for a healthy immune system and good nutrition.